EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer Summit 202520-22 February, Paris
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-PO6 | Maternal obesity induced trained immunity on the development of Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) in offspring | Moonhyung Lee |  Received |
 |
|||
| 1-PO1 | Selective targeting of class I histone deacetylases with new derivatives of ursodeoxycholic acid as a novel treatment strategy for bile duct cancer | Francisco Javier Caballero-Camino | Received |
|
|||
| 1-PO5 | Diagnosis of patients with fibrolamellar carcinoma: a Dutch nationwide study | Alicia Furumaya | Received |
|
|||
| 1-PO4 | Prediction of nodal status on preoperative MRI for patients with intrahepatic cholangiocarcinoma: an apparent diffusion coefficient-based machine learning model | Flavio Milana | Received |
|
|||
| 1-PO8 | Insights into the GALAD Score: a new optimal cut-off for hepatocellular carcinoma | Endrit Shahini | Received |
|
|||
| 1-PO3 | Patterns of Extrahepatic Metastasis and Their Impact on Oncological Outcomes in HCC Patients Treated with Atezolizumab Plus Bevacizumab | Erwan Vo Quang | Received |
|
|||
| 1-PO9 | Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation | Lorenza Di Marco | Received |
|
|||
| 1-PO7 | Impact of MBOAT7 rs641738 polymorphism on prognosis of metabolic dysfunction-associated steatotic liver disease patients with hepatocellular carcinoma | Marta Guariglia | Received |
|
|||
| 2-PO5 | ALBI grade and serum PIVKA-II changes during treatment drive clinical outcomes among atezolizumab-bevacizumab (ATZ/BEV) treated HCC patients with stable (SD) or progressive (PD) disease | Antonia Syriha | Received |
|
|||
| 2-PO8 | Early changes in body composition parameters following locoregional treatment are associated with survival and need for liver transplantation in cirrhotic patients with hepatocellular carcinoma | Simona Parisse | Received |
|
|||
| 2-PO7 | Immune biomarkers and their network of connections in patients with hepatocellular carcinoma and liver cirrhosis associated with hepatitis C virus | ROSANGELA TEIXEIRA | Received |
|
|||
| 2-PO1 | Spatial transcriptomic profiling reveals distinct stromal and clonal dynamics in liver cancer | Ji-Hye Choi | Received |
|
|||
| 2-PO6 | Mitochondrial stress in patients with chronic hepatitis B-related hepatocellular carcinoma | Abdellah Mansouri | Received |
|
|||
| 2-PO3 | Biopsy proteomic profiling predicts long-term HCC risk in patients with Metabolic dysfunction-Associated Steato-Hepatitis | Adele Delamarre | Received |
|
|||
| 2-PO9 | FIB-4 in predicting hepatocellular carcinoma during viral hepatitis: A novel indication for an old tool | Myriam Ayari | Received |
|
|||
| 3-PO3 | Metabolic liver cancer: Profiling and validation of epigenome-wide DNA methylation markers | Samuel Antwi | Received |
|
|||
| 3-PO9 | Local control and recurrence patterns after stereotactic irradiation delivered in more than 4 fractions for hepatocellular carcinomas and liver metastases | Alizée RENAN | Received |
|
|||
| 3-PO1 | Activated Gold-Nanoparticles enhance PD-1 blockade and boost cytotoxic T cell anti-tumor responses in cholangiocarcinoma | Mirko Minini | Received |
|
|||
| 3-PO4 | EFFICACY AND SAFETY OF ATEZOLIUMAB/BEVACIZUMAB FOR HEPATOCELLULAR CARCINOMA IN A REAL-WORLD PROSPECTIVE COHORT: A 2024 UPDATE . | Bernardo Stefanini | Received |
|
|||
| 3-PO2 | Harnessing human immune system mouse models to validate NOX1 inhibition as a treatment for hepatocellular carcinoma | Zenzi De Vos | Received |
|
|||
| 3-PO8 | Assessment of Immunotherapy alone (Atezolizumab/Bevacizumab) or combined with trans-arterial chemoembolization for treatment of intermediate stage-B3 Hepatocellular Carcinoma | Hend Shousha | Received |
|
|||
| 3-PO5 | Delta hepatitis versus HBV monoinfection associated hepatocellular carcinoma: spot the difference | Mirela Chitul | Received |
|
|||
| 3-PO7 | Oncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment | Nunzia Porro | Received |
|
|||
| 4-PO3 | Preventing cholangiocarcinoma progression via a stromal dysregulation and an immune infiltration triggered by cold atmospheric plasma | Laura Fouassier | Received |
|
|||
| 4-PO7 | Exploring the effectiveness of Machine Learning Algorithms in predicting Non-viral Hepatocellular Carcinoma (NVHCC) development: A Multicenter Cross-Sectional Study | Hend Shousha | Received |
|
|||
| 4-PO9 | Tyrosine Kinase Inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients | Hend Shousha | Received |
|
|||
| 4-PO1 | An immature neutrophil signature associated with response to transarterial chemoembolization | Salem Nizami | Received |
|
|||
| 4-PO5 | Leveraging normothermic liver machine perfusion as a platform to establish tumour directed ex-situ treatment | Felix Julius Krendl | Received |
|
|||
| 4-PO6 | Added-value of positron emission tomography imaging to alpha-fetoprotein score in predicting hepatocellular carcinoma recurrence after liver transplantation | Alina Pascale | Received |
|
|||
| 4-PO8 | HCC is the leading indication for liver transplantation in HCV-infected patients in the direct-acting antivirals era (single centre experience) | Sona Franková | Received |
|
|||
| 4-PO2 | Deciphering the Glycosylation Status of Programmed Cell Death-Ligand 1 and its regulation by Aurora Kinase A in Hepatocellular Carcinoma | Clarissa Joy Garcia | Received |
|
|||
| 5-PO9 | Neoadjuvant chemotherapy as a tool of systemic control following portal vein embolization before major liver resection in patients with locally advanced intrahepatic cholangiocarcinoma | Mariia Bilych | Received |
|
|||
| 5-PO7 | Real-World Analysis of Systemic Therapy Sequences After Atezolizumab and Bevacizumab in Hepatocellular Carcinoma: Insights from the IMMUreal Cohort | Florian P. Reiter | Received |
|
|||
| 5-PO3 | Leucine diet targeting leucyl-tRNA synthetase 1 enhances N-glycan biosynthesis translation and overcomes chemoresistance | Liu Haining | Received |
|
|||
| 5-PO1 | BAP1 mutations reveal a subgroup of BTC with distinct prognosis and benefit from adjuvant therapy: a retrospective biomarker analysis externally validated in a reconstructed global cohort. | Antonella Cammarota | Received |
|
|||
| 5-PO8 | Hepatocyte Nuclear Factor 1 Alpha Variants as Risk Factor for Hepatocellular Carcinoma Development with and without Diabetes Mellitus. | Mohamed Abdel-Samiee | Received |
|
|||
| 5-PO6 | Prognostic factors for survival in patients with intermediate-stage unresectable hepatocellular carcinoma treated with lenvatinib or atezolizumab plus bevacizumab. | Naoki Uchihara | Received |
|
|||
| 5-PO4 | Circulating tumour DNA analysis for predicting clinical outcomes in advanced liver cancer: insights from tumor fraction, and DELFI score | Venkata Ramana Mallela | Received |
|
|||
| 5-PO5 | LEN-New FP as a promising second-line therapy for patients with unresectable hepatocellular carcinoma refractory to atezolizumab bevacizumab, durvalumab tremelimumab, and lenvatinib | Susumu Maruta | Received |
|
|||
| 5-PO2 | Characterization of SLU7 silencing as a new strategy to treat cancer | Carla Rojo | Received |
|
|||
| 6-PO2 | A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab | Mara Persano | Received |
|
|||
| 6-PO6 | Novel prooncogenic mechanism of ABCC3/B3H7 in liver metastasis using a hepatocellular cancer model | Cecilia Zertuche-Martínez | Received |
|
|||
| 6-PO5 | Changes in incidence of primary liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in Scotland between 2000 and 2019 | Berkay Yanik | Received |
|
|||
| 6-PO1 | Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk | Irene Olaizola | Received |
|
|||
| 6-PO9 | Treatment with combination transarterial chemoembolization and Lenvatinib plus sequential microwave ablation have improved the survival of Barcelona clinic livercancer stage B2 in Bangladesh | Ahmed Sarwar Murshed | Received |
|
|||
| 6-PO4 | Development of liver cancer-derived organoids for drug screening and disease modelling | Silvia De Siervi | Received |
|
|||
| 6-PO3 | Characterization of the peripheral lymphoid and myeloid compartments in hepatocellular carcinoma patients after combined immunotherapy | Pablo Sarobe | Received |
|
|||
| 7-PO3 | Short-period-related lifestyle changes significantly and long-lastingly impact HCC in MASLD via body composition modifications: a multicenter clinical study. | Mario Romeo | Received |
|
|||
| 7-PO7 | Living Donor Liver Transplantation for HCC patients with Macroscopic Portal Vein Tumor Thrombosis | volkan ince | Received |
|
|||
| 7-PO9 | Democratizing access to healthcare through Point of Care Testing (POCT) | Gavin Hooper-Newton | Received |
|
|||
| 7-PO1 | In-situ vaccination with Flt3L elicits immune responses against hepatocellular carcinoma and synergizes with checkpoint blockade therapy | Isabella Lurje | Received |
|
|||
| 7-PO6 | Unveiling the Role of ZBED4 in Hepatocellular Carcinoma: Evidence From the Pan-cancer Analysis and Multiple Databases | Tongyu Lin | Received |
|
|||
| 7-PO4 | A Dynamic Contrast Enhanced Ultrasound Based Risk Prediction Model for the diagnosis of Hepatocellular Carcinoma in the grey area of CEUS-LI RADS: The PERSoN4 Model. | Linda Galasso | Received |
|
|||
| 8-PO6 | Durvalumab/Tremelimumab in real life: results of a prospective cohort | Franois Villeret | Received |
|
|||
| 8-PO9 | Primary Clear cell adenocarcinoma of the liver and the risk of multiple primary gastrointestinal malignancies | Belal Hamed | Received |
|
|||
| 8-PO3 | SHiNE-UK a national evaluation of hepatocellular carcinoma surveillance and management | Christopher Mysko | Received |
|
|||
| 8-PO1 | Therapeutic potential of targeting Processing-bodies in Metabolic Dysfunction-Associated Steatohepatitis and hepatocellular carcinoma | Noémie Gellée | Received |
|
|||
| 8-PO4 | Diagnosis of extrahepatic cholangiocarcinoma in the presence of bile duct stricture using proteomic profiling: a proof-of-concept | Arthur Marichez | Received |
|
|||
| 8-PO2 | Novel chemotherapy ively induces double-strand DNA breaks and death in naďve and Cisplatin-resistant cholangiocarcinoma tumours | Irene Olaizola | Received |
|
|||
| 8-PO8 | LENVATINIB IS HIGHLY EFFECTIVE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RELATED TO BOTH NON ALCOHOL-RELATED STEATOHEPATITIS AND ALCOHOL-RELATED ETIOLOGY: A PROPENSITY SCORE ANALYSIS | Rodolfo Sacco | Received |
|
|||
| 8-PO7 | Combinatorial effect of sorafenib, valproic acid and metformin in a fluorescent xenotransplant of hepatocellular carcinoma. | Edgar Xchel Franco-Juárez | Received |
|
|||
| 8-PO5 | Investigation of GLI1 ive inhibitor for targeted therapy in Intrahepatic Cholangiocarcinoma: a step towards precision medicine | Savino Paradiso | Received |
|
|||
| 9-PO5 | Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death | Ciro Celsa | Received |
|
|||
| 9-PO8 | Data Mining Reveals Novel Gene Drivers of Lenvatinib Resistance in Hepatocellular Carcinoma | Cyrollah Disoma | Received |
|
|||
| 9-PO4 | TLR3 and interferon-gamma signaling synergistically increases drug efficacy in cholangiocarcinoma | Antonio T. Pinto | Received |
|
|||
| 9-PO9 | Incidence and prevalence of hepatocellular carcinoma in patients coinfected with HBV and HDV. | Stefano Laviola | Received |
|
|||
| 9-PO3 | Differential efficacy of irinotecan-based chemotherapy in distinct mouse strain backgrounds in cholangiocarcinoma models | Lisa Wende | Received |
|
|||
| 9-PO1 | Role of the splicing factor poly(rC)-binding protein 2 in cholangiocarcinoma malignancy and chemoresistance | Maria Reviejo | Received |
|
|||
| 9-PO6 | Comparative Survival Analysis of Hepatocellular Carcinoma Patients With and Without Secondary Primary Tumors | Pompilia Radu | Received |
|
|||
| 9-PO2 | Optimising an ex-vivo pre-clinical model of hepatocellular carcinoma (precision cut tumour slices) to study tumour biology and drug sensitivity | Keara Kirkness | Received |
|
|||
| 9-PO7 | Transarterial embolization with ethylene vinylalcol copolymer (EVOH) for spontaneous rupture of unresectable hepatocellular carcinoma: an oncological role beyond haemostasis? | Parmigiani Maria | Received |
|
|||
| 10-PO4 | Characterization of hepatic lesions by LI-RADS during the surveillance of advanced liver disease in the prospective cohort of cases with congenital univentricular heart after Fontan palliation. | Luisa Cavalletto | Received |
|
|||
| 10-PO8 | Setting the record straight: Utility and outcomes of HCV treatment in patients with HCV related HCC. | Maria Fernanda Guerra Veloz | Received |
|
|||
| 10-PO2 | TROP2 as a potential therapeutic target in cholangiocarcinoma | Hanna Isele | Received |
|
|||
| 10-PO6 | Association of Hyperglycemia and Outcomes after Hepatectomy for Hepatocellular carcinoma | Angelina Ebner | Received |
|
|||
| 10-PO3 | Pivotal role of Fibroblast growth factor 21 in protecting against liver injury and decelerating hepatocarcinogenesis by regulating oxidative stress response in non-steatotic liver disease | Hanna Redeker | Received |
|
|||
| 10-PO1 | Manipulating tumour associated macrophages to elicit anticancer effects in a spheroid-engrafted precision-cut liver slice model of human hepatocellular carcinoma | Amy Collins | Received |
|
|||
| 10-PO5 | A tale of two cities: HCC surveillance inequalities in the United Kingdom | Maria Qurashi | Received |
|
|||
| 10-PO9 | Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma | Giuliana Amaddeo | Received |
|
|||
| 11-PO3 | Blockade of CD73 expressed by hepatocellular tumour endothelium improves CD8 T cell recruitment | Rosemary Faulkes | Received |
|
|||
| 11-PO2 | Cabozantinib-Induced Mitochondrial Activation of the cGAS-STING Pathway Enhances the Antitumor Immunity in Experimental Hepatocellular Carcinoma | Patricia Rider | Received |
|
|||
| 11-PO9 | The hepatocyte nuclear factor 1 homeobox A (HNF1A) gene polymorphism and AFP serum levels in Egyptian HCC patients | Mohamed Abdel-Samiee | Received |
|
|||
| 11-PO7 | Improvement of quality of care and patient satisfaction for patients with hepatocellular carcinoma via implementation of a specialist nurse interim analysis of the HCC-Care Nurse pilot study | Larissa Pajancic | Received |
|
|||
| 11-PO6 | Statins in patients with advanced HCC treated with Atezolizumab/Bevacizumab: a propensity score-matched analysis from a prospective multicentric dataset. | Marco Vicardi | Received |
|
|||
| 11-PO8 | Real-world efficacy and safety of first-line Gemcitabine-Cisplatin-Immune Checkpoint Inhibitor in patients with advanced biliary tract cancers: a single-centre experience | Joycelyn Lee | Received |
|
|||
| 11-PO1 | Therapeutic potential of Human antigen R inhibition in chronic liver disease and hepatocellular carcinoma | Mickaël Jouve | Received |
|
|||
| 11-PO5 | Somatic copy number alterations in circulating cell-free DNA as a predictive biomarker for hepatocellular carcinoma: insights from a proof-of-concept study | Elisa Pinto | Received |
|
|||
| 12-PO5 | Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab-Bevacizumab for hepatocellular carcinoma | Leonardo Stella | Received |
|
|||
| 12-PO8 | Enhancing liver biopsy accuracy with contrast-enhanced ultrasound: insights from Cracow University Hospital | Agnieszka Czapska | Received |
|
|||
| 12-PO4 | Data from a multinational registry on liver transplantation after immune checkpoint inhibition in hepatocellular carcinoma patients | Ulrike Bauer | Received |
|
|||
| 12-PO7 | The good and the bad for patients with HCC in the pre and post COVID pandemic years | David Barnes | Received |
|
|||
| 12-PO6 | Immune checkpoint inhibitors as adjunctive therapy with locoregional treatment in patients with advanced hepatocellular carcinoma is tolerable and improves disease-free survival: real-world experience | Tarek Hassanein | Received |
|
|||
| 12-PO1 | Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma | Maider Huici Izagirre | Received |
|
|||
| 12-PO9 | A machine learning-based algorithm to improve surveillance of hepatocellular carcinoma in patients with liver cirrhosis | Silvia Cagnin | Received |
|
|||
| 12-PO2 | Impact of molecular alterations on outcomes of advanced biliary tract cancers treated with cisplatin, gemcitabine, and durvalumab: a multicenter, real-world study across Europe, Asia, and America | Federico Rossari | Received |
|
|||
| 12-PO3 | Epigenetic regulation of liver endothelial cells as a novel target to boost immunotherapy efficacy in hepatocellular cancer | Saad Rehman | Received |
|
|||
| 13-PO9 | Mongolian liver cancer ethiologic description analysis | Naranjargal Dashdorj | Received |
|
|||
| 13-PO4 | Review of 20 years of liver tumor collection in the French liver biobank network | Bruno Clément | Received |
|
|||
| 13-PO6 | 18F-fluorodeoxyglucose positron emission tomography coupled with computed tomography (18F-FDG PET/CT) as a recurrence prognosis tool in liver transplantation for hepatocellular carcinoma | Olivier Detry | Received |
|
|||
| 13-PO7 | Alcohol etiology: a key factor in the management of hepatocellular carcinoma | Anoďsia Courtois | Received |
|
|||
| 13-PO3 | Machine learning for early detection of cholangiocarcinoma in a population-level cohort | Jan Clusmann | Received |
|
|||
| 13-PO1 | Molecular characterization of hemochromatosis tumors and iron overload in hepatocellular carcinoma | Patricia de la Cruz-Ojeda | Received |
|
|||
| 13-PO2 | Final safety and efficacy results from the phase 1b/2a study of fostrox plus lenvatinib in second/third line patients with advanced hepatocellular carcinoma who progressed on immunotherapy | Fredrik Oberg | Received |
|
|||
| 13-PO5 | Prognostic role of serum Glypican-3 measurement in patients with hepatocellular carcinoma | Marta Guariglia | Received |
|
|||
| 14-PO7 | Preliminary results from the hellenic registry for intrahepatic cholangio-carcinomas | Dimitrios N. Samonakis | Received |
|
|||
| 14-PO4 | HIPERIA Study: Impact of clinically significant portal hypertension on the prognosis of patients with compensated cirrhosis and hepatocellular carcinoma undergoing systemic treatment. | Antonio Guerrero | Received |
|
|||
| 14-PO8 | Fibroscan role in determining the patients who are at high risk for developing HCC in 1000 cirrhotic Egyptian patients | Abdel Ghani Badran | Received |
|
|||
| 14-PO9 | Outcome associated prognostic factors in hepatocellular carcinoma patients undergoing resection: study of clinical, pathological, and serological aspects | Agnčs Soriano | Received |
|
|||
| 14-PO1 | Therapeutic Targeting of Neddylation in Hepatoblastoma: Novel Approaches in Pediatric Liver Cancer | Leidy Estefanía Zapata-Pavas | Received |
|
|||
| 14-PO3 | Role of post-translational modification (PTM) in liver cancer: HuR SUMOylation | Claudia M. Rejano-Gordillo | Received |
|
|||
| 14-PO2 | Inhibition of Strawberry Notch 1 represses hepatobiliary carcinoma development | Stephanie Roessler | Received |
|
|||
| 15-PO7 | The tumor burden score is a novel prognostic indicator for intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization: A preliminary single-center study | Merve Guzel Dirim | Received |
|
|||
| 15-PO1 | Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study. | Annalisa Cespiati | Received |
|
|||
| 15-PO3 | Analysis of the peripheral immune context by single-cell transcriptomics in patients with hepatocellular carcinoma treated with immunotherapy | Beatriz Minguez | Received |
|
|||
| 15-PO6 | Real-world experiences of cabozantinib after immunotherapy in patients with unresectable HCC | Kaoru Tsuchiya | Received |
|
|||
| 15-PO8 | Advancing diagnostic adequacy and patient safety in liver lesions: The role of EUS-guided liver biopsy in modern oncology | shilpa jain | Received |
|
|||
| 15-PO2 | Dissecting the role of tumor endothelial cells (ECs) and macrophages in hepatocellular carcinoma (HCC) with VETC angiogenesis provides potential targets of treatment | Camilla De Carlo | Received |
|
|||
| 15-PO4 | Evaluating microbeam radiotherapys effect on normal liver tissue: a step towards understanding its potential as a treatment | Cheuk Ting Wu | Received |
|
|||
| 16-PO9 | ALBI score as a predictor of survival in patients with hepatocellular carcinoma treated by transarterial radioembolization. | Alvaro Suárez | Received |
|
|||
| 16-PO8 | Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: A single-center pilot study | Spyridon Pantzios | Received |
|
|||
| 16-PO2 | Pattern of expression, immune contexture and clinical correlates of tertiary lymphoid structures (TLS) in biliary tract cancer (BTC) | Eleonora Borghi | Received |
|
|||
| 16-PO4 | Recapitulating the liver tumour endothelium in vitro: a tool for novel drug delivery studies | Megan Bannister | Received |
|
|||
| 16-PO7 | Prognosis of HCC in French Guiana and the French West Indies Compared to a TertiaryCenter in the le-de-France Region | Alolia ABOIKONI | Received |
|
|||
| 16-PO3 | DNA replication stress as a potential therapeutic target in hepatocellular carcinoma | Nina Desboeufs | Received |
|
|||
| 16-PO1 | Lipid and cell cycling perturbations driven by the HDAC inhibitor romidepsin render liver cancer vulnerable to receptor tyrosine kinase targeting and immunologically active | Celia Sequera | Received |
|
|||
| 16-PO6 | Evaluation of epidemiological trends and recurrence rates in unresectable hepatocellular carcinoma treated with microwave ablation: a 14-year study | andrea mormone | Received |
|
|||
| 17-PO6 | Economic evaluation of the hepatocellular carcinoma early detection and treatment presidential initiative in Egypt | Mohamed AbdAllah | Received |
|
|||
| 17-PO7 | Analysis of disease-specific therapeutic efficacy of atezolizumab plus bevacizumab in advanced hepatocellular carcinoma | Sae Yumita | Received |
|
|||
| 17-PO2 | Breaking Barriers for Intensive Care Admission in Patients with Advanced HCC on Immunotherapy | Marta Fortuny | Received |
|
|||
| 17-PO4 | Pattern of progression and post-progression survival in intermediate stage hepatocellular carcinoma. An analysis of the TACE 2 trial | Jack Shi Jie Yuan | Received |
|
|||
| 17-PO8 | Effects of portal vein thrombosis on morbidity and mortality in hepatocellular carcinoma | Zülal &304;stemihan | Received |
|
|||
| 18-PO6 | TACE combined with ICIs plus MTT after 125I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis (PATENCY ?) | Mei Junhao | Received |
|
|||
| 18-PO7 | The Size - Growth Rate Relationship in Hepatocellular Carcinoma | Dhanushan Gnanendran | Received |
|
|||
| 18-PO2 | Unveiling SLC2A3 upregulation in intrahepatic Cholangiocarcinoma: insight into metabolic reprogramming and patient prognosis | Michela Anna Polidoro | Received |
|
|||
| 18-PO1 | The usefulness of novel cholangiocarcinoma cell lines with enhanced resistance to cisplatin or 5-fluorouracil to study mechanisms of chemoresistance | ELISA LOZANO | Received |
|
|||
| 18-PO5 | Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma. | Sara Ascari | Received |
|
|||
| 18-PO3 | Sex shapes microbiota-epigenetics interplay in HCC development rewiring mitochondrial dynamics | Guerrieri Francesca | Received |
|
|||
| 18-PO4 | Annotation-free classification of liver cancer in whole slide images with multi-view feature representation-based one-way domain adaptation | Sunghong Park | Received |
|
|||
| 18-PO9 | Real world data and outcomes of liver resection in patients with hepatocellular carcinoma | mzamo mbelle | Received |
|
|||
| 18-PO8 | KAIGI HCC A web-based platform for discussion of hepatocellular carcinoma (HCC) treatment opportunities. | Rainer Geunther | Received |
|
|||
| 19-PO4 | Integrated Single-Cell RNA and Chromatin Accessibility profiling reveals epigenetic drivers of tumor heterogeneity in cholangiocarcinoma | Yoonhee Jung | Received |
|
|||
| 19-PO2 | Blocking RIPK3 impacts mitochondrial dynamics, endoplasmic reticulum stress and inflammation during murine chemical-induced hepatocarcinogenesis | André Cardador | Received |
|
|||
| 19-PO6 | The ALBI score as a tool to optimise allocation to immunotherapy in patients with hepatocellular carcinoma: insights from a multicentre cohort | Birgit Schwacha-Eipper | Received |
|
|||
| 19-PO7 | Hepatic arterial infusion chemotherapy combined with camrelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma: a retrospective study | Wei Dong | Received |
|
|||
| 19-PO5 | miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients | Clara Vianello | Received |
|
|||
| 19-PO1 | Antitumoral activity of G9a inhibitors in hepatocellular carcinoma and its potential combination with immune checkpoint inhibitors. | MAITE GARCIA | Received |
|
|||
| 19-PO9 | Urban and Rural Differences in Hepatocellular Carcinoma: A Retrospective Analysis from Southern Transylvania | Elena Rezi | Received |
|
|||
| 20-PO8 | Evaluation of the effect of 35-dimaleamylbenzoic acid on preneoplastic lesions in a model of chemical hepatocarcinogenesis. | Karina González-García | Received |
|
|||
| 20-PO5 | Lipid involvement in modeling macrophage phenotype in primary liver cancer | BARBARA OLIVIERO | Received |
|
|||
| 20-PO7 | PERIHILAR CHOLANGIOCARCINOMA LANDSCAPE IN ROMANIA | Raluca Maria Stanciulescu | Received |
|
|||
| 20-PO2 | Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma | Paula Olaizola | Received |
|
|||
| 20-PO6 | Updated Network Meta-Analysis of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: Consistent Role of TACE | Jihyun An | Received |
|
|||
| 20-PO1 | Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments | Frederic SALTEL | Received |
|
|||
| 20-PO3 | Machine and deep learning for non-invasive detection of esophageal varices in hepatocellular carcinoma patients | Asier Rabasco Meneghetti | Received |
|
|||
| 21-PO1 | Analysis of intrahepatic cccDNA and HBV-DNA in patients with hepatocellular carcinoma attributed to non-HBV etiologies | Mónica Higuera | Received |
|
|||
| 21-PO6 | The evolving treatment landscape of advanced biliary cancer (ABC): a real-world overview of the last two decades | Eleonora Borghi | Received |
|
|||
| 21-PO8 | High serum interleukin-6 and interleukin-8 levels are associated with tumor burden and poor prognosis in patients with hepatocellular carcinoma | Marta Guariglia | Received |
|
|||
| 21-PO9 | Epidemiology of hepatocellular carcinoma (2016-2023). The epidemic of metabolic associated steatotic liver disease has not yet reached us | Andrés García | Received |
|
|||
| 21-PO5 | Clinical relevance in liver cancer patients and cholephilic characteristics of microbial bile acids conjugates | Rocio Macias | Received |
|
|||
| 21-PO4 | Prognostic Value of Imaging-Detected Immune-Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab | Dong Ho Lee | Received |
|
|||
| 21-PO2 | The alpha-1 Pi*MZ genotype is an independent risk factor for hepatocellular carcinoma development in patients with advanced chronic liver disease | Lorenz Balcar | Received |
|
|||
| 21-PO7 | Predicting Hepatocellular Carcinoma in CHC patients using FIB4 and FIB6: A Longitudinal Study on non-invasive risk assessment models | Riham Soliman | Received |
|
|||
| 21-PO3 | The A-B-C cluster-based classification reveals distinct outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab | Claudia Campani | Received |
|
|||
| 22-PO8 | Clinical characteristics and outcomes in patients diagnosed with hepatocellular carcinoma receiving resection or ablation in England | Betina Blak | Received |
|
|||
| 22-PO3 | The prognostic impact of comorbidities in patients with hepatocellular carcinoma: a multicenter observational study | Elisa Pinto | Received |
|
|||
| 22-PO4 | Development of small molecule degrader of G1 to S phase Transition 1 (GSPT-1) for the hepatocellular carcinoma treatment. | Robert Dyjas | Received |
|
|||
| 22-PO5 | CD147 as a biomarker of hepatocellular carcinoma. Use of AV- CD147 extracellular vesicles as a diagnostic tool. | Ángela Rojas | Received |
|
|||
| 22-PO2 | OGT and c-Myc promote non-canonical activation of gene expression by EZH2 in hepatocellular carcinoma | Mirjam Zeisel | Received |
|
|||
| 22-PO6 | Integrating machine learning and mathematical modeling to predict hepatocellular carcinoma recurrence and optimize outcomes after liver transplantation | Daniel Sanchez | Received |
|
|||
| 22-PO7 | Cholangiocarcinoma in Latin America: A Multicenter Observational Study Alerts on Ethnic Disparities in Tumor Presentation and Outcomes | Pedro M Rodrigues | Received |
|
|||
| 22-PO1 | Shaping the immune microenvironment of hepatocellular carcinoma tumours: a role for senescent endothelial cells | Daniel Patten | Received |
|
|||
| 23-PO8 | Genetic variants in lipid metabolism and inflammation for HCC risk stratification and prognostication in MASLD. | Jessica Funck | Received |
|
|||
| 23-PO3 | The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024) | Lorenzo Lani | Received |
|
|||
| 23-PO5 | MicroRNAs as promising therapeutic inhibitors of liver fibrosis and HCC. | Asha Balakrishnan | Received |
|
|||
| 23-PO2 | CRISPR/Cas9-Mediated BIRC5 Knockout Suppresses Proliferation and Migration while Promoting Apoptosis | Mahmoud Elhefnawi | Received |
|
|||
| 23-PO7 | Ethnic and racial disparities in hepatocellular carcinoma: real-world data from a Southern California clinic show worse outcomes in Hispanics/Latinos | Isabella Martinez | Received |
|
|||
| 23-PO4 | Proton-pump inhibitors and Gut Microbiome are Associated with Survival in Hepatocellular Carcinoma under Immunotherapy | Marco Sanduzzi Zamparelli | Received |
|
|||
Liver Cancer Summit 2025
20-22 February, Paris
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 20/02/2025 TO 22/02/2025
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
